Sight Sciences Announces Presentation Of Phase I Results Of The SAHARA Randomized Controlled Clinical Trial Comparing TearCare To Restasis For The Treatment Of Dry Eye Disease At The American Academy Of Optometry Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Sight Sciences, Inc. (NASDAQ:SGHT) has announced the full phase I results from the SAHARA randomized controlled trial, demonstrating that TearCare technology was superior to Restasis prescription eyedrops for the treatment of dry eye disease. The study included 345 subjects at 25 sites in 14 states. The results are expected to be published in a peer-reviewed journal in late 2023.

October 12, 2023 | 8:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The positive results from the SAHARA trial could potentially boost Sight Sciences' market position and increase demand for its TearCare technology.
The positive results from the SAHARA trial indicate that TearCare technology is superior to Restasis for the treatment of dry eye disease. This could potentially increase demand for TearCare technology and boost Sight Sciences' market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100